NEW YORK (GenomeWeb News) – Amoy Diagnostics today said that it has reached an agreement with OxOnc Development to use Amoy's ROS1 Gene Fusions Detection Kits for a pivotal clinical trial of Pfizer's Xalkori (crizotinib).

Xiamen, China-based Amoy said that it would provide the kits to the labs conducting the study in China, Korea, and Japan. It also will provide technical support for the assay, which uses real-time PCR to detect 14 different fusion products in cDNA derived from tumor tissue or body fluids.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcrips, and more.

After seeing Rich's image of the DNA double helix structure in 1973, James Watson called Rich and told him that it was the first time in 20 years he'd had a good night's sleep.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.